Skip to Content

MQX-503 Approval Status

  • FDA approved: No
  • Brand name: MQX-503
  • Dosage form: Topical Formulation
  • Company: MediQuest Therapeutics Inc
  • Treatment for: Raynaud's Disease

MQX-503 is a locally acting, topical formulation that is designed to be applied to prevent or treat the symptoms associated with Raynaud's Disease.

Development Status and FDA Approval Process for MQX-503

DateArticle
Apr 29, 2008MediQuest Therapeutics Submits New Drug Application to FDA for MQX-503 to treat Raynaud's Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide